Printer Friendly

IMMUNOMEDICS RECEIVES APPROVAL IN CANADA FOR TESTING CANCER IMAGING AGENT

 IMMUNOMEDICS RECEIVES APPROVAL IN CANADA
 FOR TESTING CANCER IMAGING AGENT
 WARREN, N.J., Jan. 13 /PRNewswire/ -- Immunomedics, Inc. (NASDAQ: IMMU), announced today that it has received approval from the biological and radiopharmaceutical sections of the Health Bureau Protectorate in Canada to commence the clinical trials for the company's colorectal cancer imaging agent, ImmuRAID(TM)-CEA. ImmuRAID-CEA consists of a monoclonal antibody fragment directly labeled in a stable fashion with the widely available, low cost radioisotope, technetium- 99m.
 Immunomedics is a biopharmaceutical company applying innovative technology in antibody selection, modification and chemistry to the development of products for the detection and treatment of cancers and infectious diseases. Integral to these products are highly specific monoclonal antibodies designed to deliver radioisotopes, chemotherapeutic agents or toxins to tumors and sites of infections or other diseases.
 -0- 1/13/92
 /CONTACT: Amy Factor of Immunomedics, 908-647-5400/
 (IMMU) CO: Immunomedics, Inc. ST: New Jersey IN: MTC SU:


GK-OS -- NY015 -- 8952 01/13/92 09:13 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 13, 1992
Words:161
Previous Article:MORTGAGE-RELATED SECURITY MARKET POSTS RECORD-BREAKING YEAR IN 1991 WITH MORE THAN HALF A TRILLION DOLLARS IN NEW ISSUANCE
Next Article:NICHOLAS YEO JOINS GENSIA EUROPE LTD. AS DIRECTOR OF MARKETING - EUROPE
Topics:


Related Articles
IMMUNOMEDICS WINS U.S. PATENT OFFICE APPEAL; BROAD U.S. PATENT ON ORGAN IMAGING ALLOWED
IMMUNOMEDICS AWARDED PATENT FOR IMAGING AND THERAPEUTIC AGENTS
IMMUNOMEDICS ALLOWED PATENT FOR NEW CANCER IMAGING & THERAPY METHODS & AGENTS: FEDERAL GRANT FOR CANCER THERAPEUTIC ALSO AWARDED
IMMUNOMEDICS FILES FOR PRODUCT MARKETING APPROVAL IN CANADA; PRODUCT CONSISTS OF ADVANCED CANCER DETECTION METHOD
IMMUNOMEDICS RECEIVES BROAD EUROPEAN PATENT FOR HIGHLY SPECIFIC CANCER TARGETING ANTIBODIES
IMMUNOMEDICS REPORTS ON LYMPHOMA IMAGING AND THERAPY PROGRESS AT CANCER CONFERENCE
IMMUNOMEDICS GRANTED THREE PATENTS IN JAPAN
IMMUNOMEDICS MAKES ADVANCES IN ANTIBODY RECONSTRUCTION AND HUMANIZATION; PROGRESS IN CANCER THERAPY PROGRAMS REPORTED
Immunomedics Awarded U.S. Patent for Therapeutic Conjugates of Toxins and Drugs
Immunomedics Wins Patent in Japan

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters